Antiblastic treatment of hematological malignancies during pregnancy poses a number of issues related to the curability of the maternal disease, the need of a prompt treatment and the potential toxicity of chemotherapy for the fetus. Here we report the results of a systematic literature search about the management of the most frequent hematological malignancies that may occur during pregnancy, focusing on specific issues related to gestational age at diagnosis, fetal toxicity and efficacy on the maternal side. The standard approach in non-pregnant women is illustrated as reference.
Hematological malignancies in pregnancy are uncommon and their incidence ranges from I in 1000 to I in 10000 deliveries (I). Since literature is limited, optimal treatment strategy should be examined and considered independently for each case, and decisions should be individualized within a multidisciplinary discussion including hematologists, neonatologists, obstetricians and nurses. In theory, the aim of treating the pregnant mother with a hematological disease is to cure the maternal disease, maintaining a viable pregnancy. Sometimes, major ethical dilemmas arise and should be openly discussed with the future mother and her family. How to deal with the possible maternal damage subsequent to treatment postponement or how to manage the possible fetal damage due to maternal treatment should be decided on individual basis. The aggressiveness of some hematological disease and the need of prompt treatment may limit the available choices. Nonetheless, a serene and shared consideration of the treatment options is usually the best strategy that leads to the most appropriate decisions. Diagnosis may be postponed due to the difficulty in identifying symptoms. Weakness, fatigue, dyspnea or pallor may be attributed to pregnancy. Anemia and leukocytosis are common during the second and third trimester. Moreover, not all diagnostic tools may be employed during pregnancy. Computed Tomography (CT) scans or Positron Emission Tomography (PET) with fluorodeoxyglucose (18F-FDG) expose the fetus to potentially dangerous ionizing radiations and should be replaced by ultrasound and magnetic resonance imaging (MRI), that is safe especially when performed without gadolinium (2) . Gestational age at diagnosis and the type of treatment needed are essential in planning clinical management. Ideally, fetal maturity should be achieved before delivery and antiblastic chemotherapy (AC) should be postponed after the first trimester. In fact, malformations peak in the first trimester, especially when antimetabolites are administered. Multi agent AC or high dose of a single drug increase this risk. Data regarding the experience with the different anti-cancer drug that are more commonly used during pregnancy are presented in Table I (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . For more details the reader is referred to the CCOPE database (www.motherisk.org). Uncertainties about the administration of AC during pregnancy are also related to physiological changes of plasma volume, possible changes in renal and hepatic function related to gestation and the lack of systematic pharmacokinetics studies. Caution should be paid not only in planning AC but also in choosing supportive care. Among anti-emetics, the use of 5-HT3 receptor antagonists or metoclopramide in the first trimester has not been associated to an increase incidence of major malformations whereas corticosteroid showed a small but significant increase in the incidence of oral cleft (23) . The use of Erythropoietin and growth factors might be considered, although consistent data on safety are lacking (24, 25) . Neutropenic fever, thrombotic or hemorrhagic episodes or an aplastic period may complicate intensive treatment and leukemia or lymphoma treatment. The safety of several antibiotics including cephalosporins and erythromycin and the potential damages to the fetus of other agents including quinolones or tetracyclines are well known (26) . Less is known of antifungal therapy but amphotericine B seems to be a reasonable choice (27) . Regarding labor, caesarean delivery is no longer mandatory (28, 29) but it should be taken into consideration in multiple myeloma with pelvic or spinal involvement in order to avoid further stress and decrease risk of spinal or pelvic fracture (30) . AC should be stopped at least three weeks before delivery in order to reduce maternal and fetal risk of complications given by an incomplete hematological recovery (3, 31, 32) . Radiation therapy (RT), should be postponed after delivery, a part the rare cases when is administered in anatomical districts far from the pelvis. A thorough planning including the consultation with a medical physicist should be implemented in each case. Long term follow-up of offspring exposed to AC or RT is needed. Due to the scanty literature on the topic prospective data and international collaboration are highly warranted.
METHODS
We systematically searched the English literature using MEDLINE and Cochrane Controlled Trials Register databases from 1971 to 2012. Combination of Medical Subject Headings terms (cancer, lymphoma, leukemia, myeloma and chemotherapy) combined with pregnancy and gestation were used. All titles and abstracts were evaluated excluding letters and editorials. Each article was evaluated to capture relevant data regarding the diagnosis and treatment of hematological malignancies during pregnancy. We then clustered data according to each hematological malignancy, with a special focus on differences in management of pregnant and non-pregnant women.
RESULTS

Lymphomas
Lymphomas are the fourth most frequent malignancies diagnosed during pregnancy accounting for 1:6000 deliveries (33) . Diagnosis requires a histological examination of a lymph node and lor a bone marrow biopsy that usually can be done safely under local anesthesia or during an elective surgery. Optimal staging in non-pregnant patients requires history, physical examination, blood tests, radiological evaluation of chest and abdomen using CT and 18F-FDG-PET. In pregnant patients, staging should be more limited: chest should be evaluated with X-ray and abdomen with ultrasound. Whole body MRI without gadolinium can be used for a thorough staging. 18F-FDG-PET should be avoided since 18F-FDG can cross placenta and reach the fetus. An expert multidisciplinary team should discuss each case individually, since lymphomas management should vary significantly depending on different histology, stage ofthe disease and gestational age. Fetus risks due to AC or RT should be accurately weighted against the consequences of a treatment delay or a suboptimal treatment of the maternal disease. In the presence of extensive and aggressive disease during the first trimester of pregnancy, termination should be discussed and AC is warranted.
Indolent Non Hodgkin Lymphomas:
Indolent non Hodgkin lymphomas (NHLs) are rarely diagnosed during pregnancy. Histological types include follicular NHL, MALT (mucosa-associated lymphoid tissue) lymphoma, mycosis fungoides, and small lymphocytic lymphoma.
A "watch and wait" approach is usually appropriate even in non-pregnant cases. Therefore, management of indolent NHLs only occasionally may pose significant fetus-maternal conflicts and AC administration during the first trimester or before delivery may be not mandatory for the majority of cases (33) . For the rare cases requiring immediate treatment, a single agent AC or combinations of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and cyclophosphamide, vincristine and prednisone (CVP) should be preferred over antimetabolite drugs such as fludarabine or radiation-labeled monoclonal antibodies that in non pregnant patients are standard option (34) . The use of anti CD20 monoclonal antibody Rituximab during pregnancy is discussed below for aggressive NHLs. Amitay-Layish et al. (35) recently reported on seven women affected by early-stage mycosis fungoides (MF) during pregnancy. Pregnancy did not change the course of MF in any of the patients. All newborns were normal. Two of the patients were treated with topical steroids during pregnancy. One patient was treated with narrow-band ultraviolet-B combined with topical steroids. The authors concluded that pregnancy appeared to have no impact on the course ofearly ME The occurrence of MALT lymphomas is strongly associated with Helicobacter Pylori (HP) infection. HP eradication with a combination of amoxicillin, clarithromycin and proton pump inhibitor leads to a high rate of NHLs remissions. This approach that excludes AC is not known to be associated to fetal malformations and may be safely and efficiently administered during pregnancy (33) . Because of the limited evidences, further studies are needed to clarify the interplay between pregnancy and indolent NHLs.
Aggressive and very aggressive Non Hodgkin Lymphomas:
This group represents the majority of NHLs cases diagnosed during pregnancy. Aggressive lymphomas include the most common diffuse large B-cell lymphoma (DLBCL), mantle lymphoma, anaplastic large cell lymphoma, and mature T-cell and NK-cell lymphomas. Very aggressive lymphomas include B or T precursor lymphoblastic/leukemia and Burkitt lymphomas. A high incidence of unusual presentation has been reported with bilateral involvement of breast (36) (37) (38) , uterus (39), cervix (40) and ovaries (41) or vagina (42, 43) , especially when a very aggressive histology has been diagnosed.
The prognosis of aggressive and very aggressive malignancies depends on disease stage, volume and prognostic score stratification at diagnosis and on prompt and intensive treatment. Standard systemic AC includes CHOP regimen for aggressive lymphomas with an addition of etoposide, ifosfamide and a number of anti-metabolites such as cytarabine and methotrexate for very aggressive NHL. Intrathecal administration of methotrexate or arabine cytoside, growth-factor support, the use of Rituximab and high dose chemotherapy with hematopoietic stem cell reinfusion may complete the treatment plan, which is mainly based on the International Prognostic Index (IPI) (44) risk stratification. Most NHLs complicating pregnancy have aggressive or very aggressive histology and are disseminated at diagnosis. Their treatment during pregnancy can be very challenging because a prompt and aggressive approach remains the main key to maximize the patient long-term disease-free survival (DFS) (33, (45) (46) (47) . However, the health of the unborn child depends primarily on the time of exposure to AC, the doses, specific AC agent given, and the treatment frequency during pregnancy (48, 49) . A conservative approach is reasonable only in a minority of women during pregnancy presenting aggressive NHLs with no systemic symptoms, an early stage, a low-volume disease and favorable IPI score. In these cases, the avoidance of a fetal exposure to AC during the first trimester and a "watch and wait" approach may be discussed. For instance, Peccatori et al. (50) reported a favorable mother and fetus outcome in a 30-years-old woman with a stage lEA low risk NHL (an anaplastic large-cell lymphoma) occurring at the 19 th week of gestation. The patient received exclusively RT at occipital cranial region obtaining a complete and long-lasting response. On the contrary, in the majority of aggressive or very aggressive NHLs arising in first trimester, physicians face problems concerning the possibility of pregnancy termination, the high risk of fetal malformations or maternal prognosis impairment secondary to suboptimal treatment. For aggressive disease occurring after the first trimester, CHOP treatment with or without addition of Rituximab remains a reasonable and safe option for the mother and the fetus (33, 46, 47) . Despite the relatively low experience in administering CHOP regimen in pregnant women affected by NHLs, similar cyclophosphamide and anthracycline-based regimens were safely used in a high number of pregnant women with breast cancer (29) . For very aggressive malignancies, CHOP or a "watch and wait" approach showed poor maternal outcome (39) . Similar to non-pregnant cases, more intensive regimens containing anti-metabolites should be preferred (45, 51, 52 ). An intensive approach is supported by the favorable mother and fetus outcome reported by Lam et al. (45) . The author described a 21-year-old white woman diagnosed with stage II Burkitt lymphoma of the head and neck occurring at 26 weeks of gestation. She was treated with 2 cycles of systemic intensive multi-agent AC, including cyclophosphamide, vincristine, doxorubicin, cytarabine, etoposide, ifosfamide, mesna, and intrathecal cytarabine with growth factor support during the second and third trimesters. She delivered a healthy, premature boy, 6 weeks after diagnosis. At 1 year after diagnosis, the patient remained disease-free and the baby remained healthy reinforcing the suggestion that combination AC given after the first trimester might be safe for the fetus with a favorable outcome for the mother (45) . A favorable outcome for the mother but an adverse outcome for the fetus was reported by Peterson et al. (52) after treating a 28-years old woman with a stage IV Burkitt NHL diagnosed at 16 weeks of gestation. McGrath regimen containing high doses of anti-metabolites and Rituximab was administered, and the mother spontaneously delivered a stillborn infant at 26 weeks of gestation.
Rituximab is a chimeric anti-CD20 monoclonal B cell-depleting antibody widely used for the treatment of CD20 positive lymphoid malignancies, as well as other hematologic and autoimmune diseases. A single course of rituximab can result in prolonged peripheral B-cell depletion. For this reason, a counseling about contraception must include the potential for delayed B-cell reconstitution for months and occasionally years after administration. Despite counseling to avoid pregnancy, Chakravarty et al. (15) reported data on 231 pregnancies with pre-conceptional or ante-partum exposure to rituximab, most resulted in uncomplicated live births. Outcome of most cases were confounded by concomitant use of potentially teratogenic medications and severe underlying disease. Among 153 pregnancies reported with known outcomes, 90 resulted in live births. Twenty-two infants were born prematurely with one neonatal death at 6 weeks. Since the known mechanism ofaction ofrituximab is CD20+ B-cell depletion, the resulting perinatal or neonatal immunosuppression and possible infection may be of particular importance. In Chakravarty et al. (15) series, 11 neonates had hematologic abnormalities; none had concomitant infections. Four neonatal infections were reported (i.e. fever, bronchiolitis, cytomegalovirus hepatitis, and chorioamnionitis). No pattern about the timing of rituximab exposure and the 4 infections was apparent: exposures ranged from 18 months before conception to treatment initiation during the third trimester of pregnancy. Two congenital malformations were identified: clubfoot in one twin, and cardiac malformation in a singleton birth. One maternal death from pre-existing autoimmune thrombocytopenia occurred. Although relatively few infections were reported by Chakravarty et al. (15) , in pregnancies exposed to rituximab, particular vigilance should focus on early signs of infection during the pregnancy or in the neonate. Because reported cases of leucopenia were asymptomatic, transient, and without infectious complications, serial monitoring of peripheral leukocytes in exposed neonates may not be warranted. However, a neonatal complete blood count at birth may be considered to assess for clinically significant cytopenias, particularly in cases when maternal exposure to rituximab occurred shortly before or during gestation. In summary, when rituximab is strongly indicated to treat life-threatening maternal extensive and aggressive NHLs, the Chakravarty et al. (15) data suggest that the risks of treatment for the fetus may be outweighed by the benefits to the mother. In all aggressive and very aggressive NHLs, maternal and fetal medicine specialists should be involved in pregnancy, delivery and neonatal monitoring, given the complexity in preparing optimal treatment plan and managing cases requiring prompt and intensive AC with or without association of monoclonal antibodies.
Hodgkin Lymphoma:
Hodgkin lymphoma (HL) is the most common hematological malignancy that occurs during pregnancy as the peak incidence coincides with the reproductive years (53) . Literature data reported a concurrent pregnancy in 3.2% of all HL (54) but its occurrence is estimate to increase due to the rising age of pregnant female and the increasing incidence of AIDS related HL (55) . HL should be considered a curable malignancy even in advanced stages and the combination of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD regimen) is commonly considered the standard of care in non pregnant patients (56) . Despite HL is the most frequent hematological cancer complicating pregnancy data on its management are still scanty. There are reports published before 1992 using combination of mustargen, vincristine, procarbazine and prednisone (MOPP regimen) and small series of more recently treated patients, but they markedly differ from each other in site, stage of disease and in period of gestation (1, 3, 33, 53, 54, [57] [58] [59] [60] [61] . As for other diseases, the decision to postpone treatment remains a major challenge because of the potential consequences for the mother. Nonetheless, for selected cases with asymptomatic limited disease, a "watch and wait" attitude can be pursued. For extensive or symptomatic disease, successful approaches have been reported using RT,single agent vinblastine and combination AC (1, 3, 33, 54, [57] [58] [59] [60] . Involved field RT has been demonstrated reasonable for early stage supra diaphragmatic disease especially for isolated axillary or cervical disease, with average embryo doses not exceeding 0.1-0.2 Gy (54) . Single agent AC such as vinblastine has been reported to allow healthy offspring and favorable outcome to mothers (33) . Both approaches may be considered reasonable options for early stage HL. A careful re-staging should be taken into consideration after delivery, with treatment completion when appropriate. For non-pregnant HL, ABVD regimen is still considered the standard of care (56) . Moreover, this regimen has been shown safe and effective at any gestational time and at any stage of disease (3, 4, 6, 53, 59, 61) inducing Bachanova and Connors (53) to suggest this regimen as the recommend choice (grade lC recommendation) in pregnant HL patients who have to be treated promptly. The safety and effectiveness of ABVD regimen were confirmed also in a small series of pregnant patients with HL and concomitant HIV infection (62) . The combination ofABVD regimen to antiretroviral agents was manageable (63) . Special attention should be paid at time of delivery when bleomycin is administered during pregnancy. In order to do not increase risk of pulmonary toxicity authors suggest to avoid concomitant oxygen administration (46) . Two older case-control series suggested that pregnancy by itself does not affect the outcome of the disease (57, 58) . MOPP regimen with or without radiotherapy obtained similar results in 26 pregnant compared to 155 non pregnant HL patients. Lishner et al. (58) reported comparable long term outcome in 48 pregnant and non-pregnant controls. In this series, fetal long term outcome was good, without an increased risk of prematurity, intrauterine growth retardation or low birth weight. The rate of stillbirth was not statistically different from the Ontario general population. In summary, based on literature data, the treatment of the majority ofHL pregnant cases is feasible and safe after an attempt discussion on potential adverse effects of AC on fetus. Pregnancy termination may be seriously considered only in the presence of aggressive or relapsing diseases, occurring early in gestation in order to avoid suboptimal treatment for the mother and threatening fetal adverse events.
Acute and chronic leukemias
Leukemias are very rare events during pregnancy.
Their prevalence have been estimated in I to 10.000 pregnancies. Acute myelogenous (AML) or lymphocytic (ALL) leukemias are the most frequent while chronic myelogenous (CML), chronic Iymhocytic (CLL) or hairy cell leukemias (HCL) are extremely rare (64) . Thrombocytemia, polycytemia and primary myelofibrosis are uncommon events in pregnancy but when they occurred an increased risk of spontaneous abortion has been reported in literature (33, 65, 66) . AL course isusually aggressive and intensive treatments should be promptly started regardless of gestational age. Diagnosis may be difficult, since a number of signs and symptoms of AL such as pallor, weakness, fatigue, dyspnea, anemia or leukocytosis may be misleading and attributed to gestation. AL diagnosis requires a morphological, immunophenotypic and cytogenetic study of peripheral blood and bone marrow that can be safely done even during pregnancy (64) . Optimal treatments options include an induction phase followed by one or more consolidation regimens. The timing, the type and the doses of anti-leukemic drugs administration are closely related to AL features. For AML, the standard of care is an induction regimen based on cytarabine and anthracycline to achieve a complete remission followed by one or two additional consolidation courses often including a bone marrow transplantation to maintain the response (64) . Despite few data exist in AML treatment in pregnancy, cytarabine administration during the first trimester has been associated with poor fetal outcome suggesting that pregnancy termination should be taken into consideration (67) . When AML occurs later, AC seems to be safer even if standard treatment increases the risk of fetal or neonatal death, intrauterine grows retardation and premature delivery especially when idarubicin is administered (64, 67) . Since fetal cardiac toxicity has been documented after anthracycline administration during pregnancy, close monitoring of cardiac fetal function is recommended (68) . Consideration should be given to early induction labor between AC cycles (67) in order to avoid delivery during an aplastic period. Acute promyelocytic leukemia (APL) is a very rare event. Its management is a challenge since APL carries a high chance of success whether it is approached as an oncologic emergency due to its high risk of morbidity and mortality caused by the occurrence of a disseminated intravascular coagulation (DIC). Simultaneous administration of AC and all trans retinoid acid (ATRA) is currently considered the standard ofcare in non-pregnant patients since it dramatically decreases the risk ofDIC and significantly improves APL outcome (5) . Teratogenicity of ATRAhas been well documented during the first trimester when the risk of malformation reaches 85% (5, 67, 69) . Its occurrence dramatically decreases during the second and third trimester suggesting that AC alone (including an anthracycline) may be the only reasonable therapeutic option during the first trimester in patients considering unacceptable a therapeutic abortion (5) . A high risk of hemorrhage should be expected if ATRA is not included in the therapeutic protocol. In these cases, a stringent clinical and laboratory monitoring of mother and fetus should be planned all over pregnancy and during delivery to promptly recognize initial signs of DIC (5, 64, 69) . Despite the limited literature, the sequential or simultaneous use of ATRA and AC might be a reasonable option for APL cases arising during second and third trimester of gestation. Sequential strategy consists in ATRA administration until a complete response is obtained, delaying AC after birth. In this case, the expected response rate in is not significantly different from that obtained from the simultaneous use of ATRA plus AC but there may be a greater number of disease relapse. A close molecular assessment of response as well as post remission therapy may be appropriate if this option is preferred (5.) Due to the high embryo-toxicity of Arsenic Trioxide, its use cannot be recommended at any gestational age (5) . ALL accounts for 11-28% of all ALs arising in pregnancy. As for the other ALs, the importance of immediate treatment cannot be underestimated, since overall survival without treatment might be as low as two months, whereas a remission rate of 65-84% can be achieved after aggressive AC regimen. Standard ALL treatment includes antimetabolites as methotrexate and a number of different AC drugs often leading to an aplastic phase with a high risk of sepsis. As for the others AL, the teratogenicity of treatment is higher during the first trimester. When diagnosed in the first trimester, abortion should be considered (64) . Despite the scanty literature, authors reported several favorable mother and fetal outcome in ALLs treated during the second and third trimester with a combination of cyclophosphamide, vincristine, daunorubicin L-asparaginase, prednisone and intrathecal methotrexate (3, 64, 69, (71) (72) (73) . As for AMLs cases treated during pregnancy, delivery should be planned in a non aplastic period and a close maternal and fetal monitoring should be recommended (3) .
In summary, the management ofALs during pregnancy should include a close discussion about pregnancy termination if ALs are diagnosed in the first trimester. If it is decided to continue the pregnancy, then the appropriate AC regimen needs to be started immediately and determined basing on ALs features, gestational age and mother preference. Ideally, delivery should be planned in a non aplastic period and a frequent fetal/mother monitoring, along with an aggressive management of potential leukemia-related complications, is necessary to obtain optimal outcomes. CML is characterized by the presence of the BCR-ABL fusion oncogene and its occurrence is a rare event during the childbearing period. Imatinib mesylate is a tyrosine kinase inhibitor targeting BCR-ABL and in CML non-pregnant cases it is recommended as the standard of care (74) . Due to the teratogenic potential effects of tyrosine kinase inhibitors reported on preclinical models, an effective contraception should be recommended to female patients during imatinib administration. Safety of imatinib mesylate administration in pregnancy is controversial even if more than 180 cases exposed to this drug during pregnancy have been already reported (75) . Outcome data are available for 125 cases (69%). Among those with known outcomes, 50% of CML affected women delivered normal infants, 28% underwent elective pregnancy terminations, 3 following the identification of abnormalities. A total of 12 infants had abnormalities, 3 of whom with strikingly similar malformations (75) . Treatment of CML during the second and third trimesters of gestation with imatinib seems to be safer, but data are still limited and the effects of chronic exposure of infants to imatinib are not known (76) . Another problem for CML patients is what is the impact on outcome of stopping treatment as soon as pregnancy is confirmed. Kuwabara et al. (77) reported poor response at restarting in 6/7 cases who interrupted imatinib mesylate for pregnancy after achieving an optimal response. In summary, despite cumulative experience already reported on imatinib mesylate exposure, doubts remain in the counseling of women who conceive while taking imatinib. It seems that although most pregnancies exposed to imatinib are likely to have a successful outcome, a risk of serious fetal malformations remains. We have at our disposal only few cases focusing on the use of other tyrosine kinase inhibitors targeting BCR-ABL during pregnancy and definitive guidelines on their efficacy and safely could not be obtained (78, 79) . A dramatic fetal outcome following transplacental transfer of dasatinib has been reported by Berveiller P et al (80) , clearly questions its safety during pregnancy. They report the case of a 23-year-old woman diagnosed with a chronic myeloid leukemia. She was treated with dasatinib while she was diagnosed as being pregnant at 7 weeks of gestation. Obstetric monitoring showed fetal hydrops associated with severe fetal bicytopenia, leading to termination of pregnancy at 16 weeks of gestation. Dasatinib concentrations were 4 ng/ml in maternal plasma (usual concentration), 3 ng/ ml in fetal plasma, and 2 ng/ml in amniotic fluid clearly demonstrating transplacental transfer of dasatinib. Moreover, fetal hematological toxicity (leukopenia and thrombocytopenia), edema, ascites, and pleural effusions described in this case report are well-known side effects of dasatinib in adults. Before the era of the tyrosine kinase inhibitors, interferon-alpha was the standard of care for CML cases. Experience in treating pregnant patients with interferon-alpha is limited but only one case of fetal malformation has been reported in a patients concurrently treated with Hydroxyurea (81). Thus, for low risk CML cases arising during first trimester refusing therapeutic abortion, an interferon-alpha treatment could be a reasonable choice. Imatinib treatment may be planned to start just after delivery following a close molecular assessment of the disease all-over the gestation. In summary imatinib mesylate is the standard of care for non-pregnant CML patients but it use in pregnancy is still controversial. Each CML case should be examined and considered independently balancing disease risk factors versus fetal risk of malformation or abortion. Regardless of the scheduled treatment, a close follow-up for mother and fetus is mandatory. On thrombocytemia, polycytemia and primary myelofibrosis, treatment options range from no therapy, aspirin alone, low-molecular-weight heparin (LMWH) to cytoreductive therapy mainly depending on the risk of maternal vascular events and pregnancy morbidity (33, 65, 66) . Low-risk women may be treated with low-dose aspirin throughout pregnancy and prophylactic low-molecular-weight heparin (LMWH) post partum, whereas LMWH throughout pregnancy and! or interferon-alpha can be required in high-risk cases (65) . Especially during the first trimester of gestation, both anagrelide and hydroxyurea should be avoided. If cytoreductive therapy is required interferon-alpha should be considered as the safest option (65) .
Unlike ALs, CLL and HCL usually have indolent clinical courses allowing for an expectant approach. Fludarabine is the standard of care in CLL and cladribine is the standard of care in HCL. Data on their use during pregnancy are lacking but animal and preclinical studies suggest that both agents may have a high teratogenic risk. Only few cases of CLL management have been described in pregnant patients (82) (83) (84) (85) (86) (87) . One case was submitted to leukapheresis to reduce leukocitosis until delivery (82) . The clinical course of the CLL case described by Gurman et al. (83) was complicated by gestational diabetes leading to a caesarean section at the 39 th weeks and a urinary tract infection. She received no other treatment for CLL and she had a normal newborn (83) . A 36-year old female became pregnant during chlorambucil administration (84) . Treatment was stopped and the course of pregnancy and fetal development were normal until the 35 th week. The occurrence of preeclampsia caused pregnancy termination by a caesarean section at 36 th week. Despite the favorable outcome of this case, chlorambucil administration in pregnancy has been discouraged by preclinical data and by the report of a gestation resulted in a newborn with a bilateral renal agenesis (85) . Only sporadic cases ofHCL has been reported (86, 87) . Interferon-alpha has been successfully used in two patients with HCL arising during pregnancy. It was well tolerated and the pregnancies went on without complications. The two infants were apparently normal at birth, and experienced normal growth and development. An additional case of HCL in pregnancy had a splenectomy and an uneventful gestation (86, 87) . In summary, CLL and HCL are rare and indolent events in pregnancy usually allowing a careful "wait and see" approach. Management of each case should be individualized taking into consideration disease features.
Multiple Myeloma
Multiple Myeloma (MM) is a malignant disease that usually affects elderly people with a mean age at diagnosis of 62 years. Only 2-5% of cases occur during childbearing age. Thus MM in pregnancy is a very rare event.
Only 28 cases have been reported in literature (88) (89) (90) . Presenting symptoms of MM in pregnancy are usually represented by bone pain and anemia, similarly to nonpregnant cases. Apparently pregnancy does not affect MM characteristics and the majority of cases described so far have an usual indolent clinical course allowing a careful "wait and see" approach and no need for AC until delivery.
Eleven MM patients received treatment during pregnancy with different AC regimens according to the time of diagnosis (88) (89) (90) (91) (92) (93) . AC schedule included cyclophosphamide, urethane and interferon as single agents or melphalan, vincristine, doxorubicin and all trans retinoid acid in combination regimens. One case received lumbar spine RT (1.5 Gy) and urethane during the first trimester of pregnancy (94) . In the Aviles and Neri series (88), 6 female delivered 6 healthy and normal newborns while they were receiving AC during first (3 cases), second (2 cases) and third (1 case) trimester of pregnancy. Special caution should be paid in the delivery planning in MM cases with pelvic or spinal involvement. A caesarean section should be considered in order to avoid further stress and to decrease the risk of spinal or pelvic fracture (90) . Lenalidomide and thalidomide are highly effective drugs in MM. Nevertheless their teratogenic potential is well known and both drugs are contra indicated in pregnant patients (95) . No data is available for bortezomib. Corticosteroids are highly effective in MM. Their use must be discussed with gynecologists and may be considered according to the gestational time (23) . Few data exist on the use ofbisphosphonates during pregnancy. Djokanovic et al. (96) reported data on 51 cases exposed to bisphosphonates during pregnancy or shortly before conception. The bisphosphonates used were alendronate (32 cases), pamidronate (11 cases), etidronate (5 cases), risedronate (2 cases), and zoledronic acid. Although in theory bisphosphonates may affect fetal bone modeling and development, the 51 cases reported to date did not show this adverse event.
CONCLUSIONS
Even if rare, the occurrence of hematological malignancies concurrently to pregnancy poses a number of special issues that deserve a multidisciplinary approach. Treatment can be life saving for the mother, but might expose the fetus to serious damage, particularly when administered during the first trimester. Thus, the mother should be properly counseled in order to make an informed decision. From our review, it appears that a number of chemotherapy regimens can be offered after the first trimester of gestation to the pregnant mother with hematological malignancies. Antracyclines are safe and might be used for treating Hodgkin and non Hodgkin lymphomas. ABVD or CHOP might be used without fetal impairment. Rituximab can be used during pregnancy, with strict maternal and fetal monitoring, particularly when severe CD20+ cell depletion is observed. In some instances, a watchful waiting approach can be used, according to gestational age at diagnosis, aggressiveness of disease and symptoms. Patients with acute leukemias are at high risk of bleeding, infection and pregnancy complications when aggressive chemotherapy is given during pregnancy, but the same may happen when delay treatment delay is chosen. Thus careful counseling, including discussion about termination of pregnancy in the first trimester, is mandatory. Patients on imatinib for a chronic myelogenous leukemia should be kept in active contraception for the risk of fetal malformation due to this and other tyrosine kinase inhibitors. ATRA should not be administered during the first trimester, as the risk of fetal malformation is high. In the very rare patients with multiple myeloma, steroids might be used to alleviate symptoms and delivery should be preferentially exploited by cesarean section.
